Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a partnership with Beijing-based DP Technology. The collaboration aims to leverage DP Tech’s AI for Science computation platform and XtalPi’s intelligent, automatic drug research and development (R&D) solutions to streamline the pre-clinical drug R&D process, thereby accelerating drug development.
XtalPi’s Platforms and Offerings
XtalPi specializes in various innovative platforms, including the ID4Inno small-molecular drug discovery platform, XupremAb antibody discovery platform, ChemArt human-computer integrated chemical synthesis service, XtalCSP crystal form prediction platform, and XtalDynamics laboratory automation technology platform. These platforms are designed to enhance efficiency and accuracy in drug discovery and development.
DP Technology’s Contributions
DP Tech applies AI, molecular dynamics, and high-performance computing for atomic scale end-to-end in-silico simulations. Its offerings include the Hermite drug computing design platform, RiDYMO enhanced dynamics platform, and macromolecular ab initio design platform. These tools are widely adopted by global researchers in pharmaceuticals, energy science, and material science.
Significance of the Partnership
By combining their expertise, XtalPi and DP Technology aim to significantly enhance the drug development process. This collaboration is expected to reduce the time and cost associated with pre-clinical R&D, ultimately bringing new and effective therapies to market more quickly.-Fineline Info & Tech
